315 related articles for article (PubMed ID: 26940836)
1. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review.
Meng F; Zhu S; Zhao J; Vados L; Wang L; Zhao Y; Zhao D; Niu Y
BMC Cancer; 2016 Mar; 16():180. PubMed ID: 26940836
[TBL] [Abstract][Full Text] [Related]
2. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.
Guo Z; Huang Y; Gong L; Gan S; Chan FL; Gu C; Xiang S; Wang S
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):451-460. PubMed ID: 29988099
[TBL] [Abstract][Full Text] [Related]
3. Androgen Deprivation Therapy and the Risk of Stroke in Patients with Prostate Cancer: An Updated Systematic Review and Meta-Analysis.
Liu R; Zhou J; Xia S; Li T
Urol Int; 2020; 104(3-4):214-221. PubMed ID: 31747673
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis.
Wang H; Sun X; Zhao L; Chen X; Zhao J
J Diabetes Investig; 2016 Jul; 7(4):629-36. PubMed ID: 27181717
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.
Zhao J; Zhu S; Sun L; Meng F; Zhao L; Zhao Y; Tian H; Li P; Niu Y
PLoS One; 2014; 9(9):e107516. PubMed ID: 25264674
[TBL] [Abstract][Full Text] [Related]
6. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
[TBL] [Abstract][Full Text] [Related]
7. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
[TBL] [Abstract][Full Text] [Related]
9. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
10. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.
Hu JC; Williams SB; O'Malley AJ; Smith MR; Nguyen PL; Keating NL
Eur Urol; 2012 Jun; 61(6):1119-28. PubMed ID: 22336376
[TBL] [Abstract][Full Text] [Related]
11. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
12. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
[TBL] [Abstract][Full Text] [Related]
13. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
[TBL] [Abstract][Full Text] [Related]
14. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
Jespersen CG; Nørgaard M; Borre M
Eur Urol; 2014 Apr; 65(4):704-9. PubMed ID: 23433805
[TBL] [Abstract][Full Text] [Related]
15. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer.
Azoulay L; Yin H; Benayoun S; Renoux C; Boivin JF; Suissa S
Eur Urol; 2011 Dec; 60(6):1244-50. PubMed ID: 21908097
[TBL] [Abstract][Full Text] [Related]
16. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
Keating NL; O'Malley AJ; Freedland SJ; Smith MR
J Natl Cancer Inst; 2010 Jan; 102(1):39-46. PubMed ID: 19996060
[TBL] [Abstract][Full Text] [Related]
17. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
Sun M; Choueiri TK; Hamnvik OP; Preston MA; De Velasco G; Jiang W; Loeb S; Nguyen PL; Trinh QD
JAMA Oncol; 2016 Apr; 2(4):500-7. PubMed ID: 26720632
[TBL] [Abstract][Full Text] [Related]
19. Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan.
Huang WK; Liu CH; Pang ST; Liu JR; Chang JW; Liaw CC; Hsu CL; Lin YC; See LC
JAMA Netw Open; 2020 Aug; 3(8):e2015189. PubMed ID: 32865575
[TBL] [Abstract][Full Text] [Related]
20. Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis.
Cui H; Wang Y; Li F; He G; Jiang Z; Gang X; Wang G
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):15-23. PubMed ID: 32814845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]